Markets Sensex Nifty

Tempsens Instruments' IPO garnered bids for 279.44 crore shares as against 1.51 crore shares on offer, resulting in a subscription of 184.07 times.

Bombay Burmah's stock surged after the Supreme Court withdrew its earlier observation on the ₹4,655 crore lease rent liability.

The Singapore International Commercial Court has dismissed the Company's challenge, holding that there was no breach of natural justice.

Jatin Gedia expects Nifty to resume its uptrend towards 24,492, while maintaining a bullish view on Bank Nifty.

IPOs raised about ₹18,349 crore in July and ₹26,302 crore in August through August 26, together accounting for nearly 96 per cent of the FY27 fundraising so far.

Bonanza, recommends Hindustan Zinc, Bank of Maharashtra and Anthem based on strong technical setups and bullish momentum.

July and August together accounted for 33 deals and ₹49,592 crore, or nearly 69 per cent of the total issue amount raised in the first eight months.

The offer received bids for 79.35 crore shares as against 2.53 crore shares on offer.

Chandan Taparia of MOFSL recommends buying Divi's Laboratories, TVS Motors and Dixon Technologies, citing strong technical setups and improving momentum.

The main source of uncertainty remains the US-Iran standoff and the continuing disruption around the Strait of Hormuz.

Gold loans stood at around ₹18.6 trillion, or nearly 11 per cent of retail credit, after growing at a 34 per cent CAGR between FY21 and FY26.

Among the basket, Fertilisers and Chemicals Travancore rose the most, rallying over 14 per cent to an intra-day high of ₹894.

Ceigall India received Letters of Acceptance from the Ministry of Road Transport & Highway for the construction of a key section of the Lada-Sarli section of NH913 in Arunachal Pradesh.

Anand James, Chief Market Strategist at Geojit Investments, has recommended three stocks, including Hindustan Zinc, Skipper and Parag Milk Foods

Shrikant Chouhan of Kotak Securities recommends buying HDFC Life Insurance and Home First Finance given their strong fundamentals.

Symbiotec Pharmalab stands out as the preferred long-term pick, backed by SBI Securities' 'Subscribe' rating and Master Capital's positive view on its specialised business.

The first principle of allocation is, 'Invest first, investigate later,' said Harini Dedhia, fund manager at Tamohara.

Emkay initiated coverage on the company with a 'Buy' rating and a target price of ₹190.

Horizon Industrial Parks' share price opened at ₹60.25 on the National Stock Exchange (NSE), a premium of 0.42 per cent above the issue price.

Symbiotec Pharmalab IPO is a mix of a fresh issue of ₹15 lakh and an offer for sale of ₹1.63 crore. The price band for the offer is set issue price band at ₹938 to ₹988 per share.